Goldman Sachs Downgrades Alere (ALR) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Goldman Sachs Downgrades Alere (ALR) to Neutral

Jefferies Downgrades Alere (ALR) to Hold Following Takeover

February 2, 2016 7:58 AM EST

Jefferies downgraded Alere (NYSE: ALR) from Buy to Hold with a price target of $56.00 (from $54.00) after the company agreed to be acquired by Abbott Laboratories.

For an analyst ratings summary and ratings history on Alere... More

Canaccord Genuity Downgrades Alere (ALR) to Hold

February 2, 2016 7:55 AM EST

Canaccord Genuity downgraded Alere (NYSE: ALR) from Buy to Hold.

For an analyst ratings summary and ratings history on Alere click here. For more ratings news on Alere click here.

Shares of Alere closed at $54.11 yesterday.

... More

Abbott (ABT) to Acquire Alere (ALR) for $56/Share

February 1, 2016 8:02 AM EST

Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing. Abbott's total diagnostics sales will exceed $7 billion after the close.

Abbott will be able to provide new, flexible, cost-effective, high-quality products to help health systems meet... More